These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18065961)

  • 21. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
    Bonaccorsi L; Nesi G; Nuti F; Paglierani M; Krausz C; Masieri L; Serni S; Proietti-Pannunzi L; Fang Y; Jhanwar SC; Orlando C; Carini M; Forti G; Baldi E; Luzzatto L
    J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
    Park K; Dalton JT; Narayanan R; Barbieri CE; Hancock ML; Bostwick DG; Steiner MS; Rubin MA
    J Clin Oncol; 2014 Jan; 32(3):206-11. PubMed ID: 24297949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
    Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
    Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
    Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
    Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
    Sun C; Dobi A; Mohamed A; Li H; Thangapazham RL; Furusato B; Shaheduzzaman S; Tan SH; Vaidyanathan G; Whitman E; Hawksworth DJ; Chen Y; Nau M; Patel V; Vahey M; Gutkind JS; Sreenath T; Petrovics G; Sesterhenn IA; McLeod DG; Srivastava S
    Oncogene; 2008 Sep; 27(40):5348-53. PubMed ID: 18542058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
    Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.
    Warrick JI; Tomlins SA; Carskadon SL; Young AM; Siddiqui J; Wei JT; Chinnaiyan AM; Kunju LP; Palanisamy N
    Mod Pathol; 2014 Apr; 27(4):609-20. PubMed ID: 24072184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 40. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.